| 0 (0%) | 03-05 23:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.86 | 1-year : | 17.82 |
| Resists | First : | 12.72 | Second : | 15.25 |
| Pivot price | 12.74  |
|||
| Supports | First : | 8.63 | Second : | 7.18 |
| MAs | MA(5) : | 9.87 |
MA(20) : | 12.91 |
| MA(100) : | 15.9 |
MA(250) : | 14.11 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 4.7 |
| RSI | RSI(14): 30.1  |
|||
| 52-week | High : | 30.1 | Low : | 8.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLPT ] has closed above bottom band by 10.9%. Bollinger Bands are 66.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.44 - 9.48 | 9.48 - 9.52 |
| Low: | 8.59 - 8.64 | 8.64 - 8.69 |
| Close: | 9.16 - 9.25 | 9.25 - 9.33 |
Thu, 05 Mar 2026
ClearPoint Neuro (NASDAQ:CLPT) Given New $18.00 Price Target at B. Riley Financial - MarketBeat
Thu, 05 Mar 2026
ClearPoint Neuro (CLPT) Target Price Lowered but Rating Maintained | CLPT Stock News - GuruFocus
Tue, 03 Mar 2026
Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (CLPT) and Journey Medical Corp (DERM) - The Globe and Mail
Sat, 28 Feb 2026
(CLPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Thu, 26 Feb 2026
$CLPT stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
Wed, 25 Feb 2026
CLPT (NASDAQ: CLPT) Rule 144 filing lists vested RSAs/RSUs; January 10b5-1 sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 30 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 45.5 (%) |
| Shares Short | 3,320 (K) |
| Shares Short P.Month | 3,040 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -67.5 % |
| Operating Margin | -59.6 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -103.2 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 1.15 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -11.15 |
| PEG Ratio | 0 |
| Price to Book value | 16.51 |
| Price to Sales | 8.01 |
| Price to Cash Flow | -21.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|